AM
AMBS.US Amarantus Bioscience Holdings Inc
- Market cap
- USD 63.0K
- P/E
- -
- P/B
- 53.19x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is AMBS.US undervalued?
Graham numberThe Graham number of Amarantus Bioscience Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Amarantus Bioscience Holdings Inc fundamental analysis
No fundamental analysis for Amarantus Bioscience Holdings Inc yet.
Amarantus Bioscience Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Amarantus Bioscience Holdings Inc
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple scleros…
Full company profileAmarantus Bioscience Holdings Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Amarantus Bioscience Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 20.0M | 74.7K | - | 95.3K | - |
| Gross Profit | 0.00 | 0.00 | -176K | -58.9K | -17.2K | - | 20.0M | 74.7K | - | 95.3K | - |
| Operating Income | -5.71M | -21.4M | -24.8M | -8.62M | -3.22M | -3.04M | 18.3M | -628K | -148K | -268K | - |
| EBITDA | -5.64M | -21.2M | -24.6M | -7.47M | -3.15M | -66.00 | 18.5M | -422K | -9.96M | -4.53M | - |
| Net Income | -15.1M | -27.3M | -25.2M | -11.6M | -4.44M | -10.6M | 18.4M | -628K | -10.2M | -4.76M | - |
| EPS | -5.03 | -5.54 | -2.84 | -0.15 | -0.07 | -0.05 | 0.07 | 0.00 | -0.02 | -0.01 | - |
| Balance Sheet | |||||||||||
| Total Assets | 1.86M | 2.26M | 11.8M | 11.1M | 10.2M | 3.48M | 24.8M | 24.9M | 14.7M | 10.2M | - |
| Total Liabilities | 9.38M | 6.33M | 20.5M | 26.7M | 28.3M | 31.4M | 33.7M | 34.4M | 34.6M | 34.9M | - |
| Shareholders' Equity | -7.52M | -4.07M | -8.69M | -15.6M | -18.0M | -27.9M | -8.96M | -9.48M | -19.9M | -24.7M | - |
| Cash & Short-term Investments | 1.03M | 214K | 176K | 49.2K | 47.2K | 829.00 | 708.00 | 46.00 | 708.00 | - | - |
| Total Debt | 1.06M | 222.00 | 2.92M | 11.4M | 10.7M | 18.7M | 19.1M | 19.2M | 19.2M | 19.1M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.47M | -11.3M | -16.0M | -2.71M | -1.95M | -1.80M | 1.02M | -82.7K | -9.93M | -4.50M | 31.9K |
| Capital Expenditure | 181K | 181K | 10.0K | 0.00 | 0.00 | 3.46K | 0.00 | 0.00 | 5.00 | 0.00 | 0.00 |
| Free Cash Flow | -3.47M | -11.5M | -16.0M | -2.71M | -1.95M | -1.80M | 1.02M | -82.7K | -9.93M | -4.50M | 31.9K |
| Ratios | |||||||||||
| ROA | -814.0% | -1,208.0% | -214.2% | -104.0% | -43.3% | -303.9% | 74.1% | -2.5% | -69.3% | -46.7% | - |
| Net Profit Margin | - | - | - | - | - | - | 91.9% | -840.7% | - | -4,995.2% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Amarantus Bioscience Holdings Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
| 2015 | USD 23.4M | 2.64 | - |
| 2014 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:150 on Jun 10, 2015.
Who owns Amarantus Bioscience Holdings Inc
Ownership data of Amarantus Bioscience Holdings Inc is not available yet.
Amarantus Bioscience Holdings Inc company profile
- Company name
- Amarantus Bioscience Holdings Inc
- Ticker
- AMBS.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 45 Wall Street, New York, NY, United States, 10005
- Phone
- 650-862-5391
- Website
- amarantus.com
About Amarantus Bioscience Holdings Inc
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.
Amarantus Bioscience Holdings Inc management
6- Dr. John Wesley Commissiong Ph.D.Chief Scientific Officer, Director & Member of Scientific Advisory Board · born 1945
- Mr. Robert Lewis HarrisCompliance Officer & Director · born 1944
- Aimee BoutcherDirector of Investor Relations
- Dr. Ravi Kiron MBA, Ph.D.Senior Vice President of Business Development · born 1960
- Dr. Brian E. HarveyChief Regulatory Advisor & Member of Board of Advisors
- Dr. Owen Garrick M.D., MBACorporate Advisor